TACTICS Trial Demonstrates Benefit With TACE Plus Sorafenib in Unresectable HCC

TACTICS Trial Demonstrates Benefit With TACE Plus Sorafenib in Unresectable HCC

529 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Masatoshi Kudo, MD from Kindai University, Japan discusses TACTICS trial demonstrates benefit with TACE plus Sorafenib in unresectable HCC at the 2018 Gastrointestinal Cancers Symposium.

 

 

 

 

keynote-062 trial, tactics trial, tace plus sorafenib, unresectable HCC, gastrointestinal, gastrointestinal cancers symposium

Up Next Autoplay